Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.35 |
| ▸ | ATP4B | P51164 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847253 | 0.84 | ALDH1A1 (0.40) | ALDH1A1KEAP1MAPTSLC6A4MPO | |
| Ammonia Solution, Strong SCHEMBL28847195 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KEAP1MAPTSLC6A4MPO | |
| SCHEMBL1020440 | 0.79 | PSEN1 (0.40) | ALDH1A1SLC6A4MPOIDO1AGXT | |
| SCHEMBL29618975 | 0.79 | PSEN1 (0.40) | ALDH1A1SLC6A4MPOIDO1AGXT | |
| SCHEMBL27629431 | 0.78 | MPO (0.40) | ALDH1A1MAPTSLC6A4MPOIDO1 | |
| SCHEMBL7197602 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KEAP1MAPTATP4AATP4B | |
| SCHEMBL5642630 | 0.76 | KCNH2 (0.39) | ALDH1A1MAPTSLC6A4MPOSLC6A2 | |
| SCHEMBL957181 | 0.76 | SLC6A4 (0.40) | ALDH1A1MAPTSLC6A4MPOSLC6A2 | |
| SCHEMBL22904292 | 0.76 | MAOA (0.41) | SLC6A4MPO | |
| SCHEMBL3067018 | 0.76 | ESR1 (0.40) | ALDH1A1MAPTSLC6A4MPOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2014151871-A9 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014151871-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | ALDH1A1 2484/4885KEAP1 1461/4885MAPT 1525/4885 |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | ALDH1A1 2229/4885KEAP1 1793/4885MAPT 2340/4885 |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | ALDH1A1 2484/4885KEAP1 1461/4885MAPT 1525/4885 |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | ALK, JAK2, JAK1 | ALDH1A1 2484/4885KEAP1 1461/4885MAPT 1525/4885 |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | ALK, JAK1, JAK2 | ALDH1A1 1644/4885KEAP1 2182/4885MAPT 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.